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Abstract
Introduction. Community-acquired pneumonia (CAP) remains one of the most acute problems of bronchopulmo-
nary pathology being the 4th in the mortality structure (after cardiovascular, cerebrovascular diseases and malignant 
neoplasms) and the 1st among all fatalities from infectious diseases. Thanks to the scientific progress achieved in the 
antibiotic therapy and vaccine prophylaxis, the death toll has decreased four times compared to its rate during the 
“pre-antibiotic era“. However, nowadays there is a steadily increasing trend in the pneumonia mortality rate in Russia. 
The only possible way to increase efficacy of CAP treatment is timely initiated rational antibiotic therapy, considering 
the possible etiologies, risk factors and the severity of the patient’s condition.
Materials and methods. The article represents the results of anonymous prospective surveys within the framework of 
the KNOCAP multi-centered research project aimed at accessing the knowledge on the fundamental issues in diagnosis 
and treatment of community-acquired pneumonia. The survey involved 222 students in their fifth- and sixth years in 
medical institute from Belgorod, Dnepr (Dnipro), Voronezh, Kiev (Kyiv) and Saratov and 110 physicians from Kras-
nodar, Saratov, Belgorod and Dnepr.
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Results and discussion. According to the results of the survey, such levels of correct answers were given by doctors 
and students, respectively: the inadmissibility of antimicrobial therapy (AMT) delay in CAP - 82% and 59%; the main 
criterion for withholding AMT - 56% and 37%; “sequential therapy” - 61% and 59%. At the same time, only 24% of 
the students and 23% of the physicians surveyed correctly reported typical mistakes in the treatment of a non-severe 
CAP with 50% or more accuracy; and in case of initial treatment, the number of correct responses was less than 28% 
for students and 45% for doctors.
Conclusion. The survey showed that both senior medical students majoring in Medical Care and general practitioners 
had a low level of knowledge in CAP treatment. Hence, curricula need to be adjusted both in medical universities and in 
health institutions for practitioners in order to inform them and, thus, improve the quality of their knowledge in this field.
Keywords
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Introduction
In Russia, more than 1.5 million people get sick with CAP 
every year (Chuchalin et al. 2010, Blumenthal 2011). The 
average indicators of incidences of CAP are 10-15%, in 
young and middle-aged people - 1-11.6%, increasing to 
25-51% in the older age group (Kruglyakova and Narysh-
kina 2014). Despite the impressive results achieved in the 
treatment of pneumonia, there is an acute problem of a 
significant decrease in the sensitivity of microorganisms 
to antibacterial drugs. The revealed triggers of microor-
ganisms’ resistance to antibiotics should be tackled, first, 
by raising the level of medical personnel’s awareness of 
the issues of AMT of infectious diseases (Bontsevich et 
al. 2015). For a timely diagnosis, rational administration 
of antimicrobial drugs and, therefore, effective therapy 
for CAP, the sound professional training of both practiti-
oners and senior students is of great importance. For this 
purpose, doctors should constantly strive to improve their 
professional activities; and in higher medical educational 
institutions across the country, the core units of pharma-
cology and clinical pharmacology should be introduced 
into the curriculum.
The aim of the study: to assess the level of senior 
medical students’ and general physicians’ basic knowl-
edge in CAP treatment by using the method of anony-
mous questioning.
Materials and methods
The survey was conducted within the KNOCAP multicen-
ter research project, which started in 2014 (the acronym 
of the project “The assessment of students’ (physicians’) 
knowledge of community-acquired pneumonia basics”) 
(Bontsevich et al. 2015, Bontsevich et al. 2017). So far, 
the results of the survey conducted in five centers have 
been obtained and analyzed. The survey involved 222 
Medical Care majors in their fifth-sixth years from five 
cities of Russia and Ukraine (42% from Belgorod, 34% 
from Voronezh, 14% from Dnepr, 5% from Kiev and 
5% from Saratov), as well as 110 physicians (23% from 
Krasnodar, 14% from Saratov, 46% from Belgorod and 
17% from Dnepr). We have also started the research in 
Chelyabinsk, Ufa, Kazan and Vladivostok and are cur-
rently accumulating data for the further analysis.
The method of anonymous questioning was used in 
this study, for which an original questionnaire was deve-
loped on the basis of current clinical recommendations 
(Chuchalin et al. 2010). In the questionnaire, the student 
was asked to enter his/her year of studies and major, indi-
cating whether s/he is taking the questionnaire for the first 
or second time, after which, s/he is supposed to complete 
the questionnaire. The physicians were additionally asked 
to specify their specialty, category and years of service in 
their specialty. The questions concerning the therapy for 
CAP are presented below (they are given without variants 
of answers):
1. Specify the regulatory documents that the respondent 
uses in the treatment of CAP.
2. Choose the reasons to suspend the onset of antimicro-
bial therapy for CAP.
3. Indicate the main criterion to terminate antimicrobial 
therapy.
4. Choose the correct definition of the concept of “se-
quential therapy” in the treatment of pneumonia.
5. Indicate the typical errors in the initial therapy for a 
non-severe CAP.
6. Enter the drug/treatment regimen for a non-severe 
CAP in a patient in the absence of risk factors and/or 
concomitant diseases, indicating the mode of adminis-
tration, frequency and dose.
7. Enter the drug/treatment regimen for a non-severe 
CAP in the patient when there are some risk factors 
and/or concomitant diseases, indicating the mode of 
administration, frequency and dose.
8. Identify if there is a subjective need for educational 
activities on adequate therapy for CAP.
The respondent was awarded 1 point for each correct 
answer, from 0.25 to 0.75 – for an incomplete answer, 
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depending on the completeness of the answer and 0 points 
for the wrong answer. Thus, with all correct answers, the 
maximum average score was 1.0. 
The following averages were assessed in the study: the 
average score  of each respondent, the average for indivi-
dual questions, the average score  for the centers (cities) 
and the average score for the entire questionnaire. The 
average completeness rate for the correct, partially correct 
and wrong answers was defined as the average level of 
response completeness (ARC), which is an equivalent for 
the average level of correct answers. Also, the patterns of 
answers to individual questions were analyzed. Since the 
questions related to the onset of CAP treatment (questions 
No.6 and No.7) require a mandatory “written” response, 
when none was provided, 0 points were assigned. All the 
information entered into the questionnaires was then en-
tered to an electronic database and processed using Mi-
crosoft Excel applications. Statistical data were processed 
through the analysis of arbitrary contingency tables using 
the Pearson’s chi-square (×2) test.
This questionnaire, as part of the above mentioned 
KNOCAP project, was held in 2016-2017 on the bases 
of Belgorod State National Research University (Bel-
gorod), Voronezh State Medical University named after 
N.N. Burdenko (Voronezh), Dnepropetrovsk State Medi-
cal Academy (Dnepr), Saratov State Medical University 
named after V.I. Razumovsky (Saratov), and Kiev State 
Medical University named after A.A. Bogomolets (Kiev). 
It should be noted that the students were trained in the 
main therapeutic majors, as well as in Pharmacology and 
Clinical Pharmacology. It is necessary to emphasize that 
this method of knowledge evaluation is relative, being 
specially developed for this study, and cannot fully reflect 
the general level of education quality in the university. 
Partial primary and intermediate results of this study were 
presented at the IACMAC-2015 (Bontsevich et al. 2015) 
and ERS-2017 (Bontsevich et al. 2017) congresses.
Results and discussion
In the first question of the questionnaire, it was required to 
specify the regulatory document (one or several) that the 
respondent used when studying the issues of managing 
patients with CAP. The following list of answers was pro-
posed: standard, order, guidelines, I prescribe treatment 
basing on my practical experience, I find it difficult to 
answer. It should be noted that the respondents could pro-
vide their own answer option or expand the one from the 
list. Most doctors (32%) use 2 or more normative docu-
ments simultaneously and 28% prefer the standard. Most 
students (30%) had difficulty in answering this question, 
which, according to the authors, is due to their lack of 
practical experience; 14% of the physicians use guideli-
nes. A significant part of the students (7%) chose the op-
tion “other” (Fig. 1).
The second question required to indicate the possible 
reasons for delaying the onset of AMT with a confirmed 
diagnosis of CAP. The ARC for this question is 84% in 
the group of doctors and 60% in the group of students 
(Fig. 2). Despite the importance of obtaining a laborato-
ry material (blood, sputum) prior to the administration of 
antibiotics, microbiological examination should not be 
the reason for the delay of AMT (Chuchalin et al. 2010, 
Chuchalin et al.2017, Yakovlev et al. 2016). Most doctors 
(82%) and a great many of students (59%) answered the 
question correctly (p <0.001).
A stable normalization of body temperature over a pe-
riod of 48-72 hours, combined with a positive clinical pic-
ture, is a key criterion for terminating AMT for a non-se-
vere CAP (Chuchalin et al. 2010). ARC for the question 
about an adequate duration of AMT is 42% in the group of 
students and 60% in the group of doctors (Fig. 3). About 
56% of doctors and 37% of students answered correctly 
(p <0.01).
The next question was aimed at assessing the respon-
dents’ knowledge of ”sequential therapy” in managing 
patients with CAP. The main idea of the sequential mode 
of antimicrobial drugs (AMD) administration is to reduce 
the duration of parenteral AMT by transferring patients to 
tableted drugs. In practice, the transition to the oral route 
of AMD administration takes place on average 2-3 days 
after the start of treatment (Avdeev 2004). Regardless of 
the importance of this treatment tactics, only 59% of stu-
dents and 61% of doctors managed to answer correctly 
(p>0.05), with the ARCs for doctors and students being 
63% and 61%, respectively (Fig. 4).
In the next question of the questionnaire, it was nec-
essary to point out the typical mistakes when beginning 
antibiotic therapy for a non-severe CAP in patients with-
out risk factors. The following AMD options were offered 
to the respondent: ampicilline+oxacilline (Ampiox); 
ciprofloxacin; cefazolin; ampicillin per os; and respira-
tory fluoroquinolones. According to the clinical guide 
(Chuchalin et al. 2010), the use of ampicillin per os is 
accompanied with a low bioavailability of the drug (40%) 
compared with amoxicillin (75-93%); cefazolin has a low 
activity against pneumococci, as well as lack of clinically 
significant activity against H. influenzae; ciprofloxacin is 
inactive against S. pneumoniae and M. pneumoniae; it is 
inappropriate to prescribe respiratory fluoroquinolones as 
a drug of choice in patients without risk factors; Ampiox 
should not be used in medical practice because of irra-
tional combination of antibiotics (Yakovlev et al. 2016). 
Less than 1% of the students and 2% of the doctors (p> 
0.05) know that the proposed AMD are inadvisable be-
cause of their ineffectiveness. Since the majority of the re-
spondents (90% of students and 84% of doctors) gave an 
incomplete correct answer, the results were divided into 
two groups: respondents with 50-75% level of correct 
answers and those with a 25% rate. The results were as 
follows: 66% of the physicians and 67.3% of the students 
gave an incomplete correct answer, referring the correct 
answer group by 25%; 20.8% of doctors and 23.6% of 
students were referred to the incomplete correct answer 
by 50-75% (p>0.05). The ARC for the question about the 
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Figure 1. Preferred choice of regulatory documents for the treatment of CAP patients
Figure 2. Responses to the question about reasons for a delayed onset of AMT in patients with a confirmed diagnosis of CAP
Figure 3. Responses to the question about the main criterion for termination antimicrobial therapy
Figure 4. Responses to the question about sequential therapy for CAP
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typical mistakes in the initial antibacterial therapy for a 
non-severe CAP is 29.5% in the group of students and 
31% in the group of doctors (Fig. 5).
The last questions served to determine the level of 
knowledge when choosing the initial AMT to manage 
patients with a non-severe CAP. The respondent had to 
independently fill in a blank field with a drug name or a 
regimen of treatment with indicating the dose, frequency 
and administration mode.
When answering the question requesting to indicate an 
optimal initial therapy for a non-severe CAP in patients 
with neither risk factors nor concomitant diseases, the 
respondents were supposed to enter amoxicillin or ma-
crolides as a drug of choice, according to the clinical re-
commendations. Though in vitro aminopenicillins do not 
cover the entire spectrum of potential pathogens, clinical 
trials did not reveal any differences in the efficacy of these 
antibiotics. Macrolides should be preferred at suspicion 
on ”atypical” etiology of the disease (S. pneumoniae and 
M. pneumoniae) (Chuchalin et al. 2010, Nie et al. 2018). 
It should be emphasized that the positive dynamics can be 
achieved in patients of this group with oral forms of AMD 
administration.
ARC for the question of treatment tactics in this group 
of patients is 20.5% in the group of students and 28% in the 
group of doctors. The correct answer was given by 5.5% 
of doctors and 4.1% of students (p>0.05). However, the 
physicians gave an incomplete correct answer (50-75%) 
significantly more often (p<0.001) (Fig.6). Therefore, a 
considerable number of the respondents made mistakes 
in selecting the initial therapy: 62% of the respondents in 
the group of students chose an AMD inconsistent with the 
clinical recommendations (26% of them indicated cepha-
losporins, 36% - protected penicillins, 16% - respiratory 
fluoroquinolones and 22% - AMD from other groups), 4% 
of students, though choosing the correct drugs for therapy, 
indicated an incorrect treatment regimen, 43% of the res-
pondents gave an incomplete correct answer (that is, they 
indicated one true drug, among which amoxicillin was 
mentioned in 65% and macrolide in 35% answers), 21% 
of the respondents left the blank empty and 12% indicated 
another treatment option; in the group of doctors: 56% 
of the respondents chose an AMD inconsistent with the 
clinical recommendations (28% selecting cephalosporins, 
59% - protected penicillins, 7% -respiratory fluoroquino-
lones, 6% - other types of AMD), 1% of the respondents 
indicated an incorrect treatment regimen, 49% of doctors 
gave an incomplete correct answer (amoxicillin - 74%, 
macrolide - 26%), 12% of the respondents left the blank 
empty (Figs. 6, 7) .
The next question required a respondent to indicate an 
optimal initial therapy for a non-severe CAP in patients 
with risk factors and/or concomitant diseases (diabetes 
mellitus, COPD, congestive heart failure, chronic renal 
failure, drug addiction, chronic alcoholism, malnutriti-
on, cirrhosis) and/or those who had taken system AMD 
for 2 or more days over the last 3 months. When ma-
naging these patients, tableted forms of AMD are also 
recommended, but the tactics of AMT for such patients 
is different, as the etiological role of Gram-negative flora 
is likely to increase (Chuchalin et al. 2010, McLaughlin 
et al. 2018, Lee et al. 2018, Cilli et al. 2018). The use 
of the following combined AMD is recommended in the 
initial therapy: amoxicillin+clavulanic acid. When there 
are risk factors for ”atypical” microflora, a combination 
of β-lactam and macrolide may be possible. An alterna-
tive to a combination therapy may be the administration 
of respiratory fluoroquinolone (levofloxacin, moxifloxa-
cin, hemifloxacin) (Marston et al. 1997, Valenza et al. 
2016, Chuchalin et al. 2017, Cillóniz et al. 2018). The 
local practice of administration of aminoglycosides 
(gentamicin, etc.), cefazolin and ciprofloxacin for CAP 
treatment should be considered erroneous, as they are 
not active against the key pathogens of CAP (Chuchalin 
et al. 2010).
ARC totaled 14% in the group of students and 23% 
in the group of doctors. Completely correct answers 
were given by less than 3% of the respondents. Howev-
er, the doctors gave an incomplete correct answer (50-
75%) significantly more often (р<0.001). At the same 
time, fairly large number of the respondents (63.8% of 
doctors and 85.5% of students, р<0.05) suggested an in-
correct scheme of managing patients with a non-severe 
CAP when there were some risk factors and/or concom-
itant diseases. (Fig. 8). The major mistakes among the 
students were: 33% of the respondents chose an AMD 
inconsistent with the clinical guidelines (70% of the re-
spondents chose cephalosporins, 8% - protected penicil-
lins, 22% - other types of AMD), 1% of students indicat-
ed a wrong treatment regimen, 49% gave an incomplete 
correct answer (that is, they indicated at least one correct 
drug, among which 7% of students indicated a combina-
tion of protected penicillins and respiratory fluoroquino-
lones, 27% - protected penicillins, 15% - a combination 
of protected penicillins and macrolide and 51% - respi-
ratory fluoroquinolones), 33% of the respondents left 
the blank empty and 10% indicated another treatment 
option; in the group of doctors: 35% of the respondents 
chose an AMD inconsistent with the clinical recommen-
dations (74% of them indicated cephalosporins, 18% - 
protected penicillins, 8% - other types of AMD), 1% of 
the respondents, though they made the correct choice of 
the drug, indicated an incorrect treatment regimen, 65% 
of the doctors gave an incomplete correct answer (32% 
of the respondents indicated only protected penicillins, 
31% - a combination of protected penicillins and macro-
lide and 37% - respiratory fluoroquinolones), 18% of the 
respondents left the blank empty.
Thus, at the decision-making stage concerning an initi-
al AMT for patients with a non-severe CAP, both students 
and doctors made a significant number of errors: the AMD 
indicated by the respondents do not always meet the clini-
cal guidelines (high frequency of administering the 3d ge-
neration cephalosporins against the drugs of choice) and 
had poor knowledge of the administration schedule (route 
of administration, frequency and dose).
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Figure 5. Responses to the question about typical mistakes in CAP treatment
Figure 6. Distribution of answers concerning the choice of optimal initial therapy for a non-severe CAP in patients with neither risk 
factors nor concomitant diseases
Figure 7. The main mistakes in the groups of students and doc-
tors (both groups together) when selecting an initial therapy for 
a non-severe CAP in patients with neither risk factors nor con-
comitant diseases
In the last question of the questionnaire, it was re-
quired to indicate whether there was a subjective need 
for educational programs on managing CAP patients. A 
considerable number of the respondents (64% of doctors 
and 63% of students) expressed the need for such kind 
of activities.
Conclusions
The conducted survey indicated that both senior Medical 
Care majors and general practitioners showed a low level 
of knowledge of CAP treatment. The greatest difficulties, 
both for students and practitioners, appeared when ans-
wering the questions about ”sequential therapy” as well 
as the questions requiring a “written” response – a re-
commended initial treatment regimen for a non-severe 
CAP. It should be admitted that the doctors coped better 
with the majority of the tasks as compared to the stu-
dents’ results, which may be due to lack of practical ex-
perience in the latter (Fig. 10). However, this fact does 
not justify the low level of theoretical competence of the 
students, though they had already studied pharmacology 
and clinical pharmacology.
In the authors’ view, the number of practical lessons 
on CAP remains insufficient for better understanding and, 
as a result, mastering the topic by the students. It is likely 
that more hours should be allocated to the questions about 
the treatment of major infectious diseases when teaching 
students of the fifth and sixth years of study. In addition, 
special training programs should be introduced to inform 
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Figure 8. Responses to the questions about an initial therapy for a non-severe CAP in patients with risk factors and/or concomitant 
diseases
Figure 10. Distribution of incorrect answers to all questions in groups of doctors and students
Figure 9. The main mistakes in the groups of students and doctors (both groups together) when selecting an initial therapy for a 
non-severe CAP in patients with risk factors and/or concomitant diseases
doctors in this field and improve their knowledge of the 
issue. Thus, future and currently practicing doctors, fa-
miliar with CAP treatment, will be able to provide timely 
and proper medical care.
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